Skip to Main Content
Contribute Try STAT+ Today

As concerns mount over a possible carcinogen found in popular heartburn medicines, the Food and Drug Administration noted that an outside laboratory that discovered traces of the contaminant used a method “not suitable” for testing. As a result, the agency is suggesting the lab may have generated higher levels of the carcinogen than what might have been found otherwise.

In a brief statement, the FDA contended that Valisure, which alerted agency officials to the presence of NDMA in heartburn pills such as Zantac, used higher temperatures in its testing than methods used by the agency. Consequently, the company, which also runs an online pharmacy, generated “very high levels” of NDMA in samples of the medicines, known as ranitidine, that it tested.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.